F
Funds
The funds writing checks into New York tech.
5 listed in healthcare
Allventure capitalseedearly stagegrowthfundaipre seedseries aventureenterprisemulti stagenyccorporate vchealthcareacceleratordeep techfintechb2bconsumerdatacryptoeuropeglobalisraelproptechco investmentcrossovercybersecuritydual useenterprise softwareholding companyhr techinfrastructureprivate equitypublic and privateresearchsaasseries bstudiothesis driven
5 funds
F
Canaan PartnersEarly-stage venture capital firm investing in visionaries with transformative ideas across therapeutics, consumer apps and deep tech.canaan.com
Canaan PartnersEarly-stage venture capital firm investing in visionaries with transformative ideas across therapeutics, consumer apps and deep tech.canaan.comF
Maverick VenturesEarly-stage investing arm of Maverick Capital, investing from seed through Series B across healthcare, AI and technology.maverickcapital.com
Maverick VenturesEarly-stage investing arm of Maverick Capital, investing from seed through Series B across healthcare, AI and technology.maverickcapital.comF
NEANew Enterprise Associates, a venture capital firm investing in technology and healthcare from seed through IPO, with offices including Menlo Park.nea.com
NEANew Enterprise Associates, a venture capital firm investing in technology and healthcare from seed through IPO, with offices including Menlo Park.nea.comF
Oak HC/FTGrowth equity firm backing healthcare and fintech founders with checks from $1M to $100M, seed to growth, with offices in Stamford CT and San Francisco.oakhcft.com
Oak HC/FTGrowth equity firm backing healthcare and fintech founders with checks from $1M to $100M, seed to growth, with offices in Stamford CT and San Francisco.oakhcft.comF
OrbiMedGlobal healthcare investment firm with roughly $20 billion under management, investing from early-stage private companies to large multinationals across biopharmaceuticals, medical devices, digital health, diagnostics and healthcare services.orbimed.com
OrbiMedGlobal healthcare investment firm with roughly $20 billion under management, investing from early-stage private companies to large multinationals across biopharmaceuticals, medical devices, digital health, diagnostics and healthcare services.orbimed.com